HRS-5041 + docetaxel + prednisone acetate

This is a **combination therapy** consisting of three active agents: HRS-5041, docetaxel, and prednisone acetate. - **HRS-5041** is an orally administered small molecule targeting the androgen receptor (AR) by a *Proteolysis Targeting Chimera (PROTAC)* mechanism, leading to AR degradation. It is under investigational development for the treatment of metastatic castration-resistant prostate cancer (mCRPC)[2][7]. - **Docetaxel** is a well-established chemotherapeutic agent in the taxane class; it inhibits microtubule depolymerization, thereby interrupting cell division and leading to apoptosis. It is globally approved for numerous cancers, including prostate cancer. - **Prednisone acetate** is a synthetic glucocorticoid used adjunctively in prostate cancer and other malignancies to manage symptoms and as part of the standard docetaxel-containing regimens (acts as an anti-inflammatory and immunosuppressant, while mitigating certain chemotherapy side effects). This combination is being explored in early phase clinical trials for the treatment of advanced or metastatic castration-resistant prostate cancer[4].